Drospirenone enhances GPIb-IX-V-mediated platelet activation

Area of Science:

• Reproductive endocrinology
• Hematology
• Pharmacology

Background:

• Epidemiologic studies link drospirenone (DRSP)-containing contraceptives to increased thrombosis risk in women.
• The precise causal mechanisms behind this association remain unclear.

Purpose of the Study:

• To investigate the in vitro effects of drospirenone (DRSP) on coagulation parameters.
• To elucidate the probable mechanisms by which DRSP influences coagulation and platelet activation.

Main Methods:

• Assessed DRSP's impact on activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), and fibrinogen (FIB).
• Evaluated DRSP's effects on platelet activation in response to various agonists, including collagen, ADP, thrombin, U46619, adrenaline, and botrocetin/von Willebrand factor (VWF).

Main Results:

• DRSP did not directly affect APTT, PT, TT, FIB, or platelet aggregation induced by collagen, ADP, thrombin, U46619, or adrenaline.
• DRSP significantly enhanced botrocetin/VWF-induced platelet aggregation and glycoprotein Ib-IX-V (GPIb-IX-V) signaling.
• This enhancement was inhibited by blocking progesterone receptor membrane component 1 (PGRMC1), ADP scavenging, or cyclooxygenase inhibition.

Conclusions:

• Drospirenone (DRSP) facilitates VWF receptor GPIb-IX-V-mediated platelet activation without directly inducing it.
• The progesterone receptor membrane component 1 (PGRMC1) may be involved in DRSP's prothrombotic effects.
• Inhibiting thromboxane A2 production and ADP receptor activation could mitigate DRSP-associated side effects.